Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
3(15%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
6
30%
Ph phase_1
1
5%
Ph phase_3
1
5%
Ph phase_4
8
40%
Ph not_applicable
3
15%

Phase Distribution

1

Early Stage

6

Mid Stage

9

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
1(5.3%)
Phase 2Efficacy & side effects
6(31.6%)
Phase 3Large-scale testing
1(5.3%)
Phase 4Post-market surveillance
8(42.1%)
N/ANon-phased studies
3(15.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

20

all time

Status Distribution
Active(4)
Completed(4)
Other(12)

Detailed Status

unknown12
Completed4
Recruiting3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (5.3%)
Phase 26 (31.6%)
Phase 31 (5.3%)
Phase 48 (42.1%)
N/A3 (15.8%)

Trials by Status

recruiting315%
completed420%
not_yet_recruiting15%
unknown1260%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT07057778Phase 2

Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP

Not Yet Recruiting
NCT06146972Phase 4

Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis

Recruiting
NCT06244628Phase 3

Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD

Recruiting
NCT03855007Phase 4

The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment

Completed
NCT04928066Phase 4

The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA

Completed
NCT05626348Phase 4

The Clinical Efficacy of Immunomodulators in RA Patients

Recruiting
NCT05281068Phase 2

The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT05302024Phase 2

Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT05216757Phase 2

Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)

Unknown
NCT04830644Phase 2

A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

Unknown
NCT01554917Phase 4

A Study of Iguratimod in Patients With Active Rheumatoid Arthritis

Completed
NCT04515706Not Applicable

Iguratimod in Systemic Sclerosis

Unknown
NCT02936375Phase 2

The Iguratimod Effect on Lupus Nephritis (IGeLU)

Unknown
NCT01850966

Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis

Completed
NCT02839941Not Applicable

Iguratimod in Kidney Transplant Recipients

Unknown
NCT03054545Not Applicable

Iguratimod as Treatment for Refractory Lupus Nephritis

Unknown
NCT03023592Phase 1

Study of Iguratimod in Sjögren's Syndrome

Unknown
NCT01548001Phase 4

Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis

Unknown
NCT02275299Phase 4

Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis

Unknown
NCT01893151Phase 4

Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI

Unknown

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20